Extracellular ATP, hemopexin and vascular alterations in Preeclampsia* - Hemopexin, ATP and preeclampsia

niversitair Medisch Centrum Groningen0 个研究点目标入组 295 人开始时间: 待定最近更新: 2024年5月6日

适应症

试验速览

暂无简介。

•Experiment 1: Pregnant women who have been diagnosed to be at increased risk for developing preeclampsia, i.e. women who have been diagnosed with pre-existent hypertension, diabetes mellitus, vasculitis, renal disease, autoimmune disease, malignancy, or women with preeclampsia in their previous pregnancy, women carrying twins. ;Experiment 2:
•Preeclamptic patients:
•* Preeclampsia defined by the ISSHP criteria (see onderzoeksprotocol)
•* Primigravid
•* Age: >/<= 18 years and <40 years;Pregnant women who deliver preterm
•* preterm delivery, i.e. before 36 weeks
•* Age: >/<=18 years and <40 years;Pregnant women who deliver a growth restricted baby
•* IUGR * Age: >/<=18 years and <40 years;Normal pregnant women:
•* Primigravid
•* Age: >/<= 18 years and <40 years;Control non-pregnant women :
•* Healthy nulligravid women
•* Age: >/<= 18 years and <40 years

•Experiment 1: pregnant women without an increased risk of developing preeclampsia;Experiment 2:
•Preeclamptic women:
•Diagnosis of pre-existent hypertension,
•diabetes mellitus,
•vasculitis,
•renal disease,
•autoimmune disease,
•malignancy, ;Healthy pregnant women:
•* Multiparity
•* Multiple pregnancy
•* Fetal growth retardation
•* Other pregnancy complications
•* Hypertension
•* Any known chronical illnesses
•* Age: <18 years and >40 years
•* smoking;Control non-pregnant women:
•* Multiparity
•* Age: <18 years and >40 years
•* Existence of any known diseases
•* smoking;pregnant women with preterm delivery
•Diagnosis of
•Treated pre-existent hypertension,
•diabetes mellitus,
•vasculitis,
•renal disease,
•autoimmune disease,
•malignancy,
•signs of infection

发起方